ロード中...
Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
BACKGROUND: High sustained virological response at 12 weeks after end of treatment (SVR12) with 12 weeks of simeprevir and sofosbuvir±ribavirin (SMV+SOF±RBV) has been demonstrated in hepatitis C virus genotype 1 (HCV-1) but is based on limited data. Therefore, we performed a meta-analysis of availab...
保存先:
| 出版年: | BMJ Open Gastroenterol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4780041/ https://ncbi.nlm.nih.gov/pubmed/26966547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2015-000056 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|